NEW YORK, July 8, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH" or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a leading multi-state, vertically integrated cannabis operator, today announced that it will hold a conference call on Monday, August 5, 2024, at 8:30 AM ET following the release of its second quarter 2024 financial results.The earnings conference call may be accessed by dialing 1 (888) 390-0605. A live webcast will also be available on the Investor Relations section of the AWH websi ...

AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock ("Common Stock") and warrants to purchase an equal num ...

AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock (“Common Stock”) and warrants to purchase an equal nu ...

Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and oper ...

Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------|-------------------------------------------| | | | | For the transition | ______ | | Commission | 001-34810 | | A ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Nicole Sandford - CEO Sandy Milligan - President Torsten Hombeck - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Maggie Boeye - William Blair Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. Follo ...

Aspira (AWH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $10.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this diagnostic and bio-analytical company would post a loss of $0.39 per share when it actually produced a loss of $0.30, delivering a surprise of 23.08%.Over the last four quarters, the ...

Aspira Women's Health Reports First Quarter 2024 Financial Results Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, to ...

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for ...